News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
727,587 Results
Type
Article (44000)
Company Profile (312)
Press Release (683275)
Multimedia
Podcasts (73)
Webinars (13)
Section
Business (211866)
Career Advice (2097)
Deals (36396)
Drug Delivery (100)
Drug Development (82296)
Employer Resources (176)
FDA (16734)
Job Trends (15322)
News (356151)
Policy (33415)
Tag
Academia (2708)
Accelerated approval (5)
Adcomms (20)
Allergies (89)
Alliances (52468)
ALS (90)
Alzheimer's disease (1403)
Antibody-drug conjugate (ADC) (135)
Approvals (16736)
Artificial intelligence (284)
Autoimmune disease (22)
Automation (16)
Bankruptcy (365)
Best Places to Work (11930)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (221)
Bladder cancer (80)
Brain cancer (27)
Breast cancer (282)
Cancer (2291)
Cardiovascular disease (177)
Career advice (1756)
Career pathing (31)
CAR-T (159)
Cell therapy (440)
Cervical cancer (19)
Clinical research (66788)
Collaboration (869)
Company closure (1)
Compensation (540)
Complete response letters (19)
COVID-19 (2675)
CRISPR (45)
C-suite (251)
Cystic fibrosis (104)
Data (2232)
Decentralized trials (2)
Denatured (30)
Depression (44)
Diabetes (272)
Diagnostics (6638)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (102)
Drug shortages (27)
Duchenne muscular dystrophy (94)
Earnings (88278)
Editorial (37)
Employer branding (22)
Employer resources (151)
Events (117162)
Executive appointments (748)
FDA (18025)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (781)
Gene editing (113)
Generative AI (26)
Gene therapy (317)
GLP-1 (729)
Government (4518)
Grass and pollen (5)
Guidances (67)
Healthcare (19537)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (116)
Indications (30)
Infectious disease (2820)
Inflammatory bowel disease (141)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (100)
Interviews (323)
IPO (16851)
IRA (41)
Job creations (3819)
Job search strategy (1494)
Kidney cancer (10)
Labor market (38)
Layoffs (481)
Leadership (18)
Legal (8128)
Liver cancer (77)
Lung cancer (324)
Lymphoma (156)
Machine learning (7)
Management (62)
Manufacturing (312)
MASH (68)
Medical device (14111)
Medtech (14116)
Mergers & acquisitions (20102)
Metabolic disorders (695)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (90)
Neuropsychiatric disorders (27)
Neuroscience (1945)
NextGen: Class of 2025 (6844)
Non-profit (4618)
Now hiring (39)
Obesity (367)
Opinion (217)
Ovarian cancer (75)
Pain (88)
Pancreatic cancer (84)
Parkinson's disease (150)
Partnered (21)
Patents (242)
Patient recruitment (113)
Peanut (49)
People (59534)
Pharmaceutical (69)
Pharmacy benefit managers (18)
Phase I (20961)
Phase II (29384)
Phase III (21812)
Pipeline (1210)
Policy (141)
Postmarket research (2582)
Preclinical (8996)
Press Release (71)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (265)
Rare diseases (384)
Real estate (6235)
Recruiting (65)
Regulatory (22865)
Reports (46)
Research institute (2459)
Resumes & cover letters (361)
Rett syndrome (5)
RNA editing (5)
RSV (43)
Schizophrenia (71)
Series A (137)
Series B (86)
Service/supplier (15)
Sickle cell disease (53)
Special edition (14)
Spinal muscular atrophy (148)
Sponsored (30)
Startups (3841)
State (2)
Stomach cancer (13)
Supply chain (69)
Tariffs (40)
The Weekly (41)
Vaccines (721)
Venture capitalists (42)
Weight loss (240)
Women's health (36)
Worklife (16)
Date
Today (70)
Last 7 days (914)
Last 30 days (2644)
Last 365 days (33535)
2025 (11017)
2024 (36219)
2023 (41136)
2022 (52397)
2021 (56994)
2020 (55612)
2019 (48407)
2018 (36441)
2017 (33541)
2016 (33139)
2015 (39358)
2014 (32941)
2013 (27985)
2012 (30243)
2011 (30847)
2010 (28809)
Location
Africa (759)
Alabama (54)
Alaska (7)
Arizona (241)
Arkansas (14)
Asia (40519)
Australia (6739)
California (6257)
Canada (2033)
China (536)
Colorado (273)
Connecticut (285)
Delaware (155)
Europe (88677)
Florida (920)
Georgia (216)
Idaho (60)
Illinois (560)
India (26)
Indiana (316)
Iowa (11)
Japan (165)
Kansas (107)
Kentucky (25)
Louisiana (11)
Maine (62)
Maryland (906)
Massachusetts (4716)
Michigan (241)
Minnesota (402)
Mississippi (2)
Missouri (88)
Montana (30)
Nebraska (25)
Nevada (64)
New Hampshire (69)
New Jersey (1762)
New Mexico (28)
New York (1776)
North Carolina (1016)
North Dakota (9)
Northern California (2714)
Ohio (209)
Oklahoma (15)
Oregon (37)
Pennsylvania (1395)
Puerto Rico (13)
Rhode Island (34)
South America (1154)
South Carolina (23)
South Dakota (1)
Southern California (2348)
Tennessee (103)
Texas (922)
United States (23721)
Utah (187)
Virginia (150)
Washington D.C. (63)
Washington State (570)
West Virginia (3)
Wisconsin (57)
727,587 Results for "cerveau technologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Cerveau Technologies Inc. and Prothena Sign Agreement to Provide Novel Tau Imaging Biomarker for Research and Development of Investigational Therapeutics for Neurodegenerative Diseases
Cerveau Technologies, Inc. today announced a research collaboration agreement with Othair Prothena Limited, a subsidiary of Prothena Corporation plc (Prothena), which will enable Prothena to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.
January 10, 2023
·
1 min read
Business
Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
Cerveau Technologies, Inc. announced a license agreement with LEXEO Therapeutics, Inc., which will enable LEXEO to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.
November 7, 2022
·
1 min read
Genetown
Cerveau Technologies Inc. and Alnylam® Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
Cerveau Technologies, Inc. announced a research collaboration agreement with Alnylam® Pharmaceuticals, which will enable Alnylam to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.
September 1, 2022
·
1 min read
Press Releases
Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology
April 16, 2025
·
4 min read
Business
Cerveau Technologies Inc. Signs Agreement with Roche to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
Cerveau Technologies, Inc. announced a research collaboration agreement with Roche Products Limited, on the use of Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.
March 10, 2022
·
1 min read
Press Releases
FOXO TECHNOLOGIES INC. ANNOUNCES EXECUTION OF A NON BINDING AGREEMENT TO ACQUIRE VECTOR BIOSOURCE INC.
March 20, 2025
·
4 min read
Press Releases
Healthcare Integrated Technologies Inc. Announces Corporate Name Change to SafeSpace Global Corporation and Ticker Symbol Update
April 24, 2025
·
2 min read
Press Releases
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary
March 13, 2025
·
5 min read
Press Releases
FOXO TECHNOLOGIES INC. PROVIDES UPDATE ON ITS BEHAVIORAL HEALTH SUBSIDIARY, MYRTLE RECOVERY CENTERS, INC.
March 12, 2025
·
3 min read
Business
Cerveau Technologies, Inc. and Nihon Med-Physics Co., Ltd. Announce Manufacturing Service Agreement for [18F]MK-6240 in Japan
Cerveau Technologies, Inc. (Cerveau) and Nihon Medi-Physics (NMP), a leading company for radiopharmaceuticals in Japan, today announced that they signed a manufacturing service agreement, in which Cerveau grants NMP the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent.
February 22, 2022
·
2 min read
1 of 72,759
Next
